CSBR Champions Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CSBR

Price (delayed)

$5.02

Market cap

$69.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.07

Enterprise value

$76.03M

?
Relative Growth: Rel. Growth: 24
Relative Strength: Rel. Strength: 16
Relative Valuation: Rel. Valuation: 27
Relative Profitability: Rel. Profitability: 22

Champions Oncology, Inc., formerly Champions Biotechnology, Inc. is a United States-based company that is engaged in the development of advanced technology solutions to personalize the development and use of oncology ...

Highlights
Champions Oncology's equity has increased by 11% YoY
CSBR's quick ratio is up by 10% year-on-year and by 5% since the previous quarter
The net income has plunged by 138% YoY but it has grown by 6% from the previous quarter
The company's EPS has shrunk by 133% YoY but it rose by 13% QoQ
The debt has soared by 133% QoQ and by 83% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.championsoncology.com
Peers: CRL EXEL CLDX

Key stats

What are the main financial stats of CSBR

CSBR stock price

How has the Champions Oncology stock price performed over time
Intraday
-5.1%
1 week
1.41%
1 month
1.21%
1 year
-24.17%
YTD
-27.35%
QTD
-18.51%

Financial performance

How have Champions Oncology's revenue and profit performed over time
Revenue
$60.66M
Gross profit
$30.22M
Operating income
-$1.02M
Net income
-$1.1M
Gross margin
49.8%
Net margin
-1.8%
The company's operating income has shrunk by 138% YoY but it rose by 10% QoQ
The net income has plunged by 138% YoY but it has grown by 6% from the previous quarter
The operating margin has plunged by 136% YoY but it has grown by 11% from the previous quarter
The net margin has shrunk by 135% YoY but it rose by 10% QoQ

Price vs fundamentals

How does CSBR's price correlate with its fundamentals

Growth

What is Champions Oncology's growth rate over time

Valuation

What is Champions Oncology stock price valuation
CSBR P/E details
P/E
N/A
P/B
17.92
P/S
1.15
EV/EBIT
N/A
EV/EBITDA
161.09
EV/Sales
1.25
The company's EPS has shrunk by 133% YoY but it rose by 13% QoQ
CSBR's P/B is 72% below its 5-year quarterly average of 68.6 and 13% below its last 4 quarters average of 21.6
Champions Oncology's equity has increased by 11% YoY
The price to sales (P/S) is 29% lower than the 5-year quarterly average of 1.7 and 19% lower than the last 4 quarters average of 1.5
The revenue has grown by 7% YoY and by 2.1% from the previous quarter

Efficiency

How efficient is Champions Oncology business performance
The ROA has plunged by 138% YoY but it has grown by 8% from the previous quarter
CSBR's ROE has shrunk by 131% YoY but it is up by 8% QoQ
The company's return on sales has shrunk by 128% YoY but it rose by 13% QoQ
The company's return on invested capital has shrunk by 126% YoY but it has surged by 52% QoQ

Dividends

What is CSBR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CSBR.

Financial health

How did Champions Oncology financials performed over time
The total assets is 15% greater than the total liabilities
The total liabilities has grown by 26% from the previous quarter and by 7% YoY
The total assets is up by 23% since the previous quarter and by 9% year-on-year
The debt is 170% higher than the equity
The debt to equity has soared by 135% from the previous quarter and by 65% YoY
The debt has soared by 133% QoQ and by 83% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.